Ocellaris Pharma, Inc., Montréal, is a special purpose company created to develop one compound to proof-of-concept. The project is fully financed by TVM Life Science Innovation II SCSp.
Ocellaris is developing a biologic adressing multiple oncology indications. Target is a member of the tumor necrosis factor (TNF) receptor family and considered highly relevant for new immuno-oncology treatments.
Caroline Fortier (CEO)